RESEARCH

Peer-Reviewed Articles

Jemsek JG, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V, Thiry A, Soccadato M, Noor MA, Giordano M. “Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination with Zidovudine plus Lamivudine, in Antiretroviral-Naïve HIV-Infected Patients.” Journal Clinical Infectious Diseases 2006 January 15 (42): 273–80. 

Jemsek JG, Hutcherson P, Harper E. “Poor Virologic Responses and Emergence of Resistance in Treatment Naïve, HIV-Infected Patients Receiving Once-Daily Didanosine, Lamivudine, and Tenofovir OF.” Journal of AIDS 2006 (in progress): 3.

Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek JG, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M. “Comparison of Once-Daily Atazanavir with Efavirenz, Each in Combination with Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV.” J Acquir Immune Defic Syndr. 2004 Aug 15; 36(5): 1011–19.

Eron, Joseph J. Jr.; Murphy, Robert L.; Peterson, Dolores; Pottage, John; Parenti, David M.; Jemsek, Joseph; Swindells, Susan; Sepulveda, Gladys; Bellos, Nicholaos; Rashbaum, Bruce C.; Esinhart, Jim; Schoellkopf, Nancy; Grosso, Robert; Stevens, Michael for the START II Study Team. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)*. AIDS 14(11):p 1601-1610, July 28, 2000.

Jemsek, J.G. and Harrison, F. (1997), “Ampicillin/sulbactam vs. cefoxitin for the treatment of pelvic inflammatory disease.” Infect. Dis. Obstet. Gynecol., 5: 319-325. https://doi.org/10.1002/(SICI)1098-0997(1997)5:5<319::AID-IDOG3>3.0.CO;2-Q

Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe J Jr, Stool E, Jemsek JG, Dellamonica P, Cross A, Dunkle L. “Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.” Ann Intern Med. 1997 Mar 1; 126(5): 355–63.

Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, Wormser GP, Jablonowski H, Jemsek JG, Cynamon M, Yangco BG, Notario G, Craft JC. “A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome.” N Engl J Med. 1996 Aug 8; 335(6): 384–91.

Holloway KL, Smith KW, Wilberger JE Jr, Jemsek JG, Giguere GC, Collins JJ. “Antibiotic prophylaxis during clean neurosurgery: a large, multicenter study using cefuroxime.” Clin Ther. 1996 Jan–Feb; 18(1): 84–94.

Eron JJ, Benoit SL, Jemsek JG, MacArthur RD, Santana J, Quinn J.B, Kuritzkes DR, Fallon MA, Rubin M. “Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.” N Engl J Med. 1995 Dec 21; 333(25): 1662–69.

Henry DH, Jemsek JG, Levin AS, Levine JD, Levine RL, Abels RI, Nelson RA Thompson D, Rudnick SA. “Recombinant human erythropoietin and the treatment of anemia in patients with AIDS or advanced ARC not receiving ZDV.” J Acquired Immune Defic Syndr. 1992; 5(8): 847–8.

Lewis RT, Duma RJ, Echols RM, Jemsek JG, Najem AZ, Press RA, Stone HH, Ton GT, Wilson SE. “Comparative study of cefotetan and cefoxitin in the treatment of intraabdominal infections.” Am J Obstet Gynecol. 1988 Mar; 158 (3 Pt 2): 728–35. Erratum in: Am J Obstet Gynecol 1989 Apr; 160(4): 1025.

Geckler RW, Eng RH, Fabian TC, Echols RM, Jemsek JG, LeFrock JL, Mogabgab WC, Wilson SE. “A multicenter comparative study of cefotetan once daily and cefoxitin thrice daily for the treatment of infections of the skin and superficial soft tissue.” Am J Surg. 1988 May 31; 155(5A): 91–95.

Wilson SE, Boswick JA Jr, Duma RJ, Echols RM, Jemsek JG, Lerner R, Lewis RT, Najem AZ, Press RA, Rittenbury MS, et al. “Cephalosporin therapy in intraabdominal infections. A multicenter randomized, comparative study of cefotetan, moxalactam, and cefoxitin.” Am J Surg. 1988 May 31; 155(5A): 61–66.

Jemsek JG, Greenberg SB, Taber L, Harvey D, Gershon A, Couch RB. “Herpes zoster-associated encephalitis: clinicopathologic report of 12 cases and review of the literature.” Medicine (Baltimore). 1983 Mar; 62(2): 81–97.

Gentry LO, Jemsek JG, Natelson EA. “Effects of sodium piperacillin on platelet function in normal volunteers.” Antimicrob Agents Chemother. 1981 Apr; 19(4): 532–33.

Jemsek JG, Martin RR, Greenberg SB, Gentry LO. “Antimicrobial susceptibility testing of Haemophilus parainfluenzae by a kinetic killing-curve method.” J Infect Dis. 1980 Mar; 141(3): 310–16.

Jemsek, JG. “Urinary enzyme excretion in the assessment of aminoglycoside nephrotoxicity.” Current Opinions: Aminoglycoside Nephrotoxicity. (Monograph), 29–31. (1980)

Jemsek JG, Gentry LO, Greenberg SB. “Malignant group 8 streptococcal endocarditis associated with saline-induced abortion.” Chest. 1979 Dec; 76(6): 695–97. 

Gentry LO, Ives RT, & Jemsek JG. “Antibacterial of piperacillin against gram negative bacteria.” Current Therapy Research 1979, 26, 175–83.

Mogabgab WJ, Pollock 8, Beville RB, Gentry LO, Jemsek JG. “Treatment of acute bacterial bronchitis and pneumonia with cefaclor.” Postgrad Med J. 1979; 55 Suppl 4: 62–6.

Wilson SZ, Martin RR, Putman M, Greenberg SB, Wallace RJ Jr, Jemsek JG. “Quantitative nasal cultures from carriers of Staphylococcus aureus: effects of oral therapy with erythromycin, rosamicin, and placebo.” Antimicrob Agents Chemother. 1979 Mar; 15(3): 379–83.

Jemsek JG, Greenberg SB, Gentry LO, Welton DE, Mattox KL. “Haemophilus parainfluenzae endocarditis. Two cases and review of the literature in the past decade.” Am J Med. 1979 Jan; 66(1): 51–57.

RESEARCH

Non-Peer-Reviewed Articles

Jemsek, JG. “Epidemic of the Ages.” Pride Magazine, Dec 2003–Feb 2004.

Jemsek, JG. “Epidemic of the Ages.” Pride Magazine, Sept–Nov 2003.

Jemsek, JG. “Epidemic of the Ages.” Pride Magazine, Jun–Aug 2003.

Jemsek, JG. “Hydroxyurea: An Alternative strategy?” Published on website www.healthcg.com/hiv. Lead article, May 30, 1998.

Jemsek, JG. “Is HIV Different in Women?” Presbyterian Focus on Women Center on Women's Health, 1996.

RESEARCH

Abstracts

Jemsek J., Hutcherson P., Harper E. “Poor virologic responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once daily triple nucleside regimen of didanosine, Lamivudine, and Tenofovir DR.” Presented at the 11th Conference on Retroviruses and Opportunistic Infections, February 2004.

Jemsek J., Arathoon E., Arlotti M., Perez C., Sosa N., Pokroviskiy V., Giordano M., Thiry A., Soccodato M. “Body fat effects of Atazanavir (ATV) and Efavirenz CEFV) each combined with fixed-dose Zidovudine (ZDV) and Lamivudine (3TC), have similar effects on body fat distribution in antiretroviral-naive patients.” Presented at the 2nd IAS conference on HIV pathogenesis and treatment, July 2003.

Badaro R., DeJesus E., Lazzarin A., Jemsek J., Clotet B., Rightmire A., Thiry A., & Wilber R. “Efficacy and safety of Atazanavir (ATV) with Ritonavir (RTV) or Saquinavir (SQV) versus Lopinavir/Ritonavir (LPV/RTV) in combination with Tenofovir (TFV) and one NRTI in patients who have experienced virologic failure to multiple HAART regimens.” Presented at the 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, July 2003.

Yeni P., MacGregor T., Gathe J., Arasteh K., Jayaweera D., Jemsek J., Hawkins T., Cameron W., Bodsworth N., McCallister S., Kohlbrenner V., Quinson A, Leith J., Sabo J., Mayers D. “Correlation of viral load reduction and plasma levels in multiple protease inhibitor experienced patients taking Tipranavir/Ritonavir in a phase IIB 1182.52 5.” Presented at the 10th Conference of Retroviruses and Opportunist Infections, February 2003.

Yeni P., MacGregor T., Gathe J., Arasteh K., Jayaweera D., Jemsek J., Hawkins T., Cameron W., Bodsworth N., McCallister S., Kohlbrenner V., Auinson A, Leith J., Sabo J., Mayers D. “Correlation of viral load reduction and plasma levels in multiple protease inhibitor (PI) experience patients taking Tipranavir/Ritonavir in a phase IIB 1182.52.” Presented at the 5th International workshop on Adverse Drug Reactions and Lipodystrophy in HIV, July 2003.

Eron J., Peterson D., Murphy R., Jemsek J., Pottage J., Parenti D., Esinhart J., Schoellkopf N., & Stevens M. “An open-labeled, randomized, comparative study of d4t +ddl +ODV versus ZDV +3TC + IDV in treatment naïve HIV-infected patients: START II.” Presented at the 5th Conference on Retroviruses and Opportunistic Infections in Chicago, IL, February 1998.

Mildvan D., Martin G., Eyster M., Jemsek J., Kagan S., Seekins D., Steigbigel D., Lee S.R., Manion D.J. “The Efavirenz clinical development team and the DMP 266024 study team: Initial effectiveness and tolerability of Nelfinavir (NFV) in combination with Efavirenz (EFV, SUSTIVA, DMP 266) in Antiretroviral therapy Naïve or nucleoside analogue experienced HIV-1 infected patients: Characterized in a phase II, open-label, multicenter study at 16 weeks.” Presented as an abstract at the 12th World AIDS Conference, Geneva, Switzerland, July 1998.

Mayers D., Jemsek J., Eyster E., Tashima K., Thompson M., Iabriola D., Ruiz N. “The Efavirenz Clinical Development Team and the DMP 266-004 Study Team: A Double blind, Placebo-controlled study to assess the safety, tolerability and antiretroviral activity of Efavirenz (EFV, SUSTIVA, DMP 266) in combination with open-label Zidovudine (ZDV) and Lamivudine (3 TC) in HIV-1 Infected patients).” Presented as an abstract at the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, July 1998.

Kagan S., Jemsek J., Mayers D., Pierone G., Manion D.J., Lee S.R.. Ruiz N. “DMP 266 024 Study Team: Initial Effectiveness and Tolerability of Nelfinavir (NFV) in Combination with Efavirenz (EFV, SUSTIVA, DMP 266) in Antiretroviral therapy Naïve or Nucleoside Analogue Experience H –1 Infected patients: Characterization in a phase II, OpenLabel, Multicenter Study at > 36 weeks (1998).”

Pierce M., Lamarca P.M., Lablonowski H., Jemsek J., Faetkenheuer G., Youle M., Bautzenberq B. “A placebo controlled trial of Clarithromycin Propylaxis against MAC Infections in AIDS patients.” Presented as an abstract to 34th ICAAC, Orlando, FL, 1994.

Moskovitz B., Wiesinger B., Jemsek J. “Randomized Comparative Study of ltraconazole for Treatment of AIDS-related Cryptococcal Meningitis.” Presented as an abstract to the National Conference on Human Retroviruses and Related Infections, Washington, D.C., December 12–16 ,1993.

Jemsek J. “Safety and efficacy of teicoplanin vs. cefazolin for the treatment of skin/soft tissue infections due to staphylococcus aureus.” Presented as an abstract to the International Congress on Chemotherapy, Stockholm, Sweden, June 1993.

Gentry L.O., Jemsek J., Natelson E.A. “The effects of sodium piperacillin on platelet function in normal volunteers." Presented as an abstract to the 20th Interscience Conference on Antimicrobial Agent and Chemotherapy, October 1980.

Jemsek J., Gentro L.O., Martin M.D. “Comparative aminoglycoside Nephrotoxicity using N-Acetyl-B Glcosaminidase.” Presented as an abstract to the 19th Interscience Conference on Antimicrobial Agent and Chemotherapy, October 1980.

Jemsek J., Martin R.R., Greenberg S.B. “Antimicrobial sensitivity studies of Haemophilus parainfluenzae using kinetic killing curves.” Presented as an abstract to the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 1979.

Jemsek J., Martin R.R., Dewitz T.S., Solis RT., McIntire L.V. “Effects of an in vitro shear stress on leukocyte morphology and function.” Presented as an abstract on the 17th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, October 1977.